National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025

PB 39 of 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025

I, Rebecca Richrdson, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 16 April 2025    

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 2—Amendments— Additional designated brands effective from 1 October 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025.

 (2) This instrument may also be cited as PB 39 of 2025.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

Schedule 2—Amendments— Additional designated brands effective from 1 October 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Largactil of the drug Chlorpromazine in the form Tablet containing chlorpromazine hydrochloride 25 mg)

Insert:

2  Section 5 (after table item dealing with the brand Estalis continuous 50/140 of the drug Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8)

Insert:

3  Section 5 (after table item dealing with the brand Levetiracetam Viatris of the drug Levetiracetam in the form Tablet 1 g)

Insert:

4  Section 5 (after table item dealing with the brand NOUMED LEVETIRACETAM of the drug Levetiracetam in the form Tablet 1 g)

Insert:

5  Section 5 (after table item dealing with the brand Penthrox (Combination Pack) of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

6  Section 5 (after table item dealing with the brand Ordine 5 of the drug Morphine in the form Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL)

Insert:

7  Section 5 (after table item dealing with the brand Micolette of the drug Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12)

Insert:

8  Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))

Insert: